Navigation Links
Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Date:9/19/2007

mg twice daily, steady-state mean trough concentrations ranged from approximately 150 -- 300 ng/ml, which are well above the EC50 (concentration required for 50% inhibition of viral replication) of RDEA806 (EC50 = 1.67 ng/ml).

Evaluation of the drug-drug interaction liability, in vitro and in vivo, demonstrated that RDEA806 is unlikely to be an inducer or inhibitor of major P450 enzymes or be affected by CYP3A4 inhibitors. When given together with ritonavir, an HIV protease inhibitor and potent inhibitor of CYP3A4, plasma levels of RDEA806 were not significantly altered. These data support preclinical data that RDEA806 may have a reduced potential for drug-drug interactions, which could ultimately lead to a safer and more convenient treatment option for patients and physicians.

"We recognize the need for new HIV drugs that demonstrate potent antiviral activity against a wide range of viral isolates, including those that are resistant to currently available NNRTIs, and that show improved safety, tolerability and reduced potential for drug-drug interactions. Yesterday's presentation of the broad spectrum of antiviral activity of RDEA806 demonstrated its in vitro activity against the majority of HIV strains carrying key reverse transcriptase mutations, including coverage of the 10 most prevalent strains of HIV found in patients failing therapy with efavirenz, marketed as Sustiva(R) by Bristol-Myers Squibb*. Based on this very favorable preclinical profile, the excellent tolerability and the high levels of exposure obtained with oral dosing in Phase 1 studies, we are moving forward to conduct a Phase 2a proof-of-concept study in HIV-infected patients, which we plan to initiate before the end of this year. The terminal half-life of up to 13 hours also gives us the opportunity to evaluate once-daily dosing in Phase 2a," said Barry D. Quart, PharmD, President and CEO.

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Ace Biosciences, Ace393, the Worlds First Commercial Vaccine for Travellers Diarrhoea Caused by Campylobacter Successfully Completes Phase I Clinical Trials
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
4. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
5. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
6. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
7. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
8. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
9. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
10. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
11. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... May 23, 2013 Anthem Blue Cross patients ... have required them to obtain their medications by mail ... and Whatley Kallas LLC.  The lawsuit, ... that Blue Cross,s mandatory mail order program announced late ... and privacy. "This settlement brings to a ...
(Date:5/23/2013)... -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative ... that it has initiated dosing in a Phase I ... therapy for the treatment of HCV infection. This study will ... to assess both the safety and antiviral efficacy of ... the treatment of chronic HCV infections and is based ...
(Date:5/23/2013)... FREDERICK, Md. , May 23, 2013  BioElectronics ... safe consumer medical devices, comments on the FDA panel ... Public Advisory Panel Reclassification – Pulsed Shortwave Therapy Meeting ... Gaithersburg, MD , USA.  The focus of the ... instructed the panel to focus solely on the application ...
Breaking Medicine Technology:Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 2Blue Cross To Allow HIV/AIDS Patients to "Opt-Out" of Mandatory Mail-Order Rx Drug Program, Announces Consumer Watchdog 3Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3BioElectronics and Pulsed Shortwave Therapy Make Progress 2
... 2 Trials in Colorectal Cancer,and in Hormone-Refractory ... FRANCISCO, Calif., June 01, 2007,/PRNewswire-FirstCall/ -- Poniard ... oncology, today announced,promising results from an interim ... of picoplatin, a new generation platinum for,the ...
... Launches 1,000-Patient Lung Cancer Diversity Study, CHICAGO, June ... the leading cause of cancer death in,African-Americans, with ... deaths expected this year.(i) Equally devastating, lung,cancer is ... men and the,second leading cause of cancer death ...
Cached Medicine Technology:Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 2Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 3Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 4Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 5Poniard Pharmaceuticals Announces Promising Data From Interim,Safety Analysis of Phase 1 Combination Trials of Picoplatin in,Colorectal and Prostate Cancers 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 2Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 3Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 4Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 5Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 6Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 7Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 8Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 9Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 10Lilly Studies Try to Shed Light on Impact of Race on Lung Cancer,Treatment 11
(Date:5/24/2013)... (PRWEB) May 25, 2013 myMEDholiday.com, a ... of healthcare providers in five important medical travel destinations ... International Patient Guide to ensure a safe and ... This 15-step manual offers tips on cost-savings, how ... plan your itinerary, and a wealth other essential advice. ...
(Date:5/24/2013)... Range Kleen Mfg. strives to “TCOTC.” Our ... from the President's desk to the Shipping Dock.” We hold ... and having passion while creating excellence and quality being results ... to do the right thing and what better way to ... by devastation. , Throughout the year Range Kleen donates to ...
(Date:5/24/2013)... 24, 2013 This week is National ... their efforts to provide the best emergency care and ... this week is also to educate the public that ... survival. Citizens are the first link, and a very ... bystander CPR after a cardiac arrest can triple a ...
(Date:5/24/2013)... for heart failure appear to have better odds of ... morning, a new study finds. Death rates and ... admitted in January, on Fridays and overnight, according to ... Saturday in Portugal at the annual meeting of the ... "The fact that patients admitted right before ...
(Date:5/24/2013)... Orlando, Florida (PRWEB) May 24, 2013 KC ... are the Title Sponsors for FreeRide836. Their oldest sons, Kyle ... Mark and Tracey Russell family and several professional kiteboarders. , ... this amazing project. "This has miraculously come together such that ... be able to participate." , 20 kite boarders will meet ...
Breaking Medicine News(10 mins):Health News:myMEDholiday.com Introduces International Patient Guide to Assist People Planning Treatment Abroad 2Health News:Range Kleen Partners with Berndes in Red Cross Promotion: Taking Care of Oklahoma 2Health News:Acadian Medics Reunite with Miracle Baby 2Health News:Monday Best Time for Hospitalization With Heart Failure, Study Says 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 2Health News:FreeRide836 Sponsor Living Fuel, The Leader in Superfood Nutrition, Announces Kiteboard Launch For This Sunday To Raise Money For Orphans In Africa 3
... widespread awareness being propagated by the Indian government many AIDS patients ... even possess the basic knowledge about AIDS.// ,Newly ... destiny dealt a cruel blow - she was infected with AIDS ... 13 years later, she has not only put up a tough ...
... few technological advancements have had the potential to revolutionize ... so on. The Internet has indeed made the world ... Internet, there has been a parallel increase in the ... Internet has of late become a playground that allows ...
... marriage, hurled at them, when they accidentally discover 'Gay' tendencies ... and the marriage appears to come to a grinding halt.// ... respiratory therapist in rural Minnesota, who in June of 2000 ... they spoke about it and wept over it, her husband ...
... or impotence can now be used in treating pulmonary ... pharmaceutical company, is marketing the drug under the brand ... approved for use in last November by the European ... as the pill, Viagra. The drug is already being ...
... Department of Pathology MLN Medical College in Allahabad recently ... pathological spectrum of oral cancer' and has uncovered some ... the tumor registry between 1990 to 2000. ... the department, 759 biopsies were of the oral cavity. ...
... obsessed with the perfect weight and figure so they follow ... phenomenon in view a comparison of several // popular diets ... study after one year, sticking with a diet—more than the ... ,Michael L. Dansinger, Ernst J. Schaefer, and Joi A. Gleason ...
Cached Medicine News:Health News:Misconceptions Put AIDS Patients In Tight-Spot 2Health News:Cyber Sex, No Longer A Fantasy Of The Mind 2Health News:Do not follow popular diets, stick to one that is best for you! 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: